title: rtPA intravenous thrombolysis in anterior choroidal artery territory stroke.
abstract: OBJECTIVE
  To study the possible specific response to recombinant tissue plasminogen activator (rtPA) thrombolysis of anterior choroidal artery (AChA) stroke.
  
  
  BACKGROUND
  Outcome and response after rtPA thrombolysis are possibly better in small-vessel infarcts, but a specific study of AChA stroke has not yet been performed.
  
  
  METHODS
  The authors proposed an open trial of IV rtPA within 7 hours in patients age 20 and 81 years with all types of internal carotid artery territory stroke if the baseline Scandinavian Stroke Scale (SSS) score was less than 48. A dose of rtPA 0.8 mg/kg was infused over 90 minutes. Of 114 consecutive patients, 9 patients (7.9%) exhibited hypodensity in the AChA territory on day 1 brain CT.
  
  
  RESULTS
  Seven of nine patients with AChA infarct had a primary early recovery within 6 hours after the initiation of rtPA infusion. In addition, recovery was complete in five patients and partial in two patients. No intracerebral hematoma was observed. Three patients had a "reinfarct syndrome" at 12, 25, and 48 hours respectively. However, in the two latter patients treated with IV heparin, the deficit disappeared again with the increase of heparin dose in one patient and disappeared spontaneously in the other patient. The overall outcome at day 90 was six total recoveries in nine patients (66%). Patients with a final good outcome had a slight "unstructured" hypodensity in the AChA territory on day 1 brain CT, whereas patients with a bad outcome had the classic "structured" hypodensity of AChA territory stroke.
  
  
  CONCLUSIONS
  These data support a specific quick response of AChA territory stroke to IV rtPA thrombolysis, probably due to the small size of the artery and of the "clot." The high frequency of the reinfarct syndrome is a clinical fact that is difficult to explain. Efficient heparin treatment after 24 hours may control the reinfarct syndrome in some patients.
authors.affiliation: Cerebrovascular Unit and Ataxia Research Center, Hôpital Neurologique, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Trouillas
authors.forename: L
authors.initials: L
authors.lastname: Derex
authors.forename: N
authors.initials: N
authors.lastname: Nighoghossian
authors.forename: J
authors.initials: J
authors.lastname: Honnorat
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.forename: P
authors.initials: P
authors.lastname: Neuschwander
authors.forename: G
authors.initials: G
authors.lastname: Riche
authors.forename: J C
authors.initials: JC
authors.lastname: Getenet
authors.forename: Y
authors.initials: Y
authors.lastname: Berthezene
authors.forename: F
authors.initials: F
authors.lastname: Turjman
authors.forename: J C
authors.initials: JC
authors.lastname: Froment
authors.lastname: territory stroke
mesh_terms: D000368:Aged; D001921:Brain / Q000000981:diagnostic imaging; D002831:Choroid Plexus / Q000098:blood supply*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D010959:Tissue Plasminogen Activator